Early Magnetic Resonance Imaging Response of the Dominant Intraprostatic Lesion After Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer and Correlation With Prostate Specific Antigen Response

Launched by UNIVERSITY OF ZURICH · Feb 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how well a specific type of imaging, called multiparametric MRI, can show changes in a dominant lesion (or tumor) in the prostate after a treatment called online adaptive stereotactic body radiotherapy (SBRT). The study aims to see if the changes observed in the MRI can be linked to levels of prostate-specific antigen (PSA), which is a marker often used to monitor prostate cancer. This research is focused on men with localized prostate cancer who are considered to be at intermediate to high risk for disease progression.

To participate in this trial, men aged 18 and older with confirmed localized prostate cancer are eligible, especially those with certain types of tumors that are more aggressive. Participants will undergo imaging and treatment without the need for small markers placed inside the prostate, making the process a bit easier. It’s important to note that those with previous prostate treatments, certain health conditions, or who might feel anxious in an MRI machine cannot join the study. If eligible, participants can expect to receive cutting-edge treatment while helping researchers learn more about effective ways to monitor and treat prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with histologically confirmed localized prostate cancer who are planned for CT- or MRI-adaptive SBRT for prostate cancer;
• • Presence of PIRADS ≥3 lesion(s) in a mpMRI correlating with Gleason ≥7 score at diagnosis;
• • Intermediate to (very) high risk localized prostate cancer (≤ cT3b and cN0);
• • ECOG performance status of 0-2;
• • Age ≥ 18 years;
• • PSMA PET ≤3 months is compulsory for high-risk prostate cancer (as part of clinical routine);
• • Written informed consent.
• • Willingness and ability to comply with schedule
• Exclusion Criteria:
• • Previous (≤10 years) local therapy of the prostate including transurethral resection of the prostate (TURP),
• • Contraindication for MRI;
• • Previous (≤10 years) radiotherapy in the pelvis;
• • Lymph node metastases or distant metastases (i.e. no localized prostate cancer);
• • Participation in a clinical trial which might influence the results of this project;
• • Claustrophobic anxiety;
• • Uncontrolled intercurrent illness;
• • Relation to investigator (family or professional)